
Rupesh Kotecha
@Rrkotecha
Followers
376
Following
99
Media
17
Statuses
68
Joined September 2018
RT @NRGonc: May is #BrainCancerAwarenessMonth! We asked @Rrkotecha, NRG-BN013 Principal Investigator, to discuss this Phase III study of si….
0
1
0
RT @PDBrownOnc: Pertinent ongoing trial NRG BN014 Proton CSI vs involved field RT for Breast CA or NSCLC LMD .(RADIATE-LM) PI @JYangMDPhD @….
0
1
0
RT @MikeChuongMD: Thanks to @QuadShotNews for highlighting our analysis.-138 pts w/ abd mets mostly LN, adrenal gland, liver.-Most lung/GI….
0
8
0
RT @MikeChuongMD: 🚀Ph2 SMART ONE trial in press.🔹1-fx SBRT on 0.35T MR-Linac.🔹2/3 targets abd/pelvis, 1/3 lung.🔹🔥🔥 plans!! Median GTV mean….
0
17
0
📢Very proud of our recent publications from @MiamiCancerInst . results of SMART ONE, proton RICE categorization, and SBRT for infra-diaphragmatic oligomets with MRgRT. something for everyone, check it out now online at @IJROBP! @MikeChuongMD
0
9
27
RT @DrLilyAngelov: Can’t wait to see wonderful colleagues and hear exciting talks from world-renowned experts at the @ClevelandClinic 17th….
0
7
0
RT @MikeChuongMD: I was supposed to present a ph3 trial concept for medically inoperable but technically resectable stage I-II pancreatic c….
0
3
0
RT @TargetedOnc: Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain me….
0
7
0
RT @TargetedOnc: Rupesh Kotecha, MD, (@Rrkotecha) discussed a machine learning tool designed to predict local failure after stereotactic ra….
0
7
0
RT @NRGonc: The NRG-BN013 phase III clinical trial was recently activated as a part of the NRG Oncology brain tumor portfolio. NRG-BN013 wi….
0
8
0
Excited to be open to accrual! Lucky number NRG BN013 - a phase 3 randomized trial of SRS vs. FSRS for intact brain mets @NRGonc @JYangMDPhD @MartinTomMD @BrainTumorDoc @DrVogelbaum @MeiPolley
2
21
68
RT @MiamiCancerInst: Congratulations to Dr. Rupesh Kotecha and our #RadOnc team at @miamicancerinst for the newly published study highlight….
0
4
0
RT @PDBrownOnc: How do we manage IDHm LGG post-INDIGO?.· Multi-disciplinary decision-making mandatory.· Vorasidenib active agent reasonable….
0
17
0
RT @MikeChuongMD: Work hard play hard! 😎💪. The @MiamiCancerInst team and @DrVogelbaum enjoyed a productive day of meetings and then the #NR….
0
3
0
RT @MikeChuongMD: @MrBeast #pancreaticcancer is one of the deadliest cancers. We need funding for practice changing #clinicaltrials. Our ab….
0
4
0
RT @MiamiCancerInst: Our #MiamiCancerInstitute experts shared the latest #cancerresearch at @ASCO 2023 this year. Presentations focused on….
0
8
0
RT @MiamiCancerInst: Haley Appel, PA-C speaks on evaluating the diagnostic performance of #leptomeningeal diagnosis with CNSide™ compared t….
0
1
0
RT @BrighamRadOnc: 📢 Come hear @HarvardRadOnc resident @NayanLamba speak at ASCO this Sunday 6/5 about the genomics of brain metastases in….
0
2
0
RT @OncLive: @Rrkotecha oral CNS track @asco use of novel PET tracer to distinguish b/w radiation necrosis & tumor progression post RT in b….
0
6
0
RT @oncologytube: 🔬 Today at the ASCO Annual Meeting 2023, where groundbreaking advancements in cancer research and treatment are taking ce….
0
3
0